Wild, Mirjam G. and Kreidel, Felix and Hell, Michaela M. and Praz, Fabien and Mach, Markus and Adam, Matti and Reineke, David and Ruge, Hendrik and Ludwig, Sebastian and Conradi, Lenard and Rudolph, Tanja K. and Bleiziffer, Sabine and Kellermair, Joerg and Zierer, Andreas and Nickenig, Georg and Weber, Marcel and Petronio, Anna Sonia and Giannini, Cristina and Dahle, Gry and Rein, Kjell A. and Coisne, Augustin and Vincentelli, Andre and Dubois, Christophe and Duncan, Alison and Quarto, Cesare and Unbehaun, Axel and Amat-Santos, Ignacio and Cobiella, Javier and Dumonteil, Nicolas and Estevez-Loureiro, Rodrigo and Fumero, Andrea and Geisler, Tobias and Lurz, Philipp and Mangieri, Antonio and Monivas, Vanessa and Noack, Thilo and Franco, Luis Nombela and Pinon, Miguel A. and Stolz, Lukas and Tchetche, Didier and Walter, Thomas and Unsoeld, Bernhard and Baldus, Stephan and Andreas, Martin and Hausleiter, Joerg and von Bardeleben, Ralph S. (2022) Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. EUROPEAN JOURNAL OF HEART FAILURE, 24 (5). pp. 899-907. ISSN 1388-9842, 1879-0844
Full text not available from this repository. (Request a copy)Abstract
Aims Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort. Method and results All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high-risk patients included (43% female, mean age 75 +/- 7 years, mean STS-PROM 7.2 +/- 5.3%), 25% was treated for an off-label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to <= 1+ was achieved in all patients with successful implantation. There were two procedural deaths and 30-day all-cause mortality was 12%. At early clinical follow-up, MR reduction was sustained and there were significant reductions of pulmonary pressure (systolic pulmonary artery pressure 52 vs. 42 mmHg, p < 0.001), and tricuspid regurgitation severity (p = 0.013). Heart failure symptoms improved significantly (73% in NYHA class I/II, p < 0.001). Procedural success rate according to MVARC criteria was 80% and was not different in patients treated for an off-label indication (74% vs. 81% for off- vs. on-label, p = 0.41). Conclusion In a real-world patient population, TMVI has a high technical and procedural success rate with efficient and durable MR reduction and symptomatic improvement.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | REPAIR; REGURGITATION; REPLACEMENT; OUTCOMES; FEASIBILITY; PROSTHESIS; Mitral valve disease; Mitral regurgitation; Transcatheter mitral valve implantation; Tendyne |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Dec 2023 12:16 |
| Last Modified: | 12 Dec 2023 12:16 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58744 |
Actions (login required)
 |
View Item |
